Brief: FDA Accepts Novan's NDA For Berdazimer Gel, 10.3% For The Treatment Of Molluscum Contagiosum With PDUFA Goal Date Of January 5, 2024

NVN Liquidation

07/03/2023 13:20

March 7 (Reuters) - Novan Inc  NOVN.O :
    * FDA ACCEPTS NOVAN’S NDA FOR BERDAZIMER GEL, 10.3% FOR THE
TREATMENT OF MOLLUSCUM CONTAGIOSUM WITH A PDUFA GOAL DATE OF
JANUARY 5, 2024
    * NOVAN INC - FDA COMPLETES FILING REVIEW OF APPLICATION
WITH NO
FILING ISSUES IDENTIFIED
    * NOVAN INC - COMPANY ALSO RECEIVED ITS PRESCRIPTION DRUG
USER FEE
GOAL DATE OF JANUARY 5, 2024

Source text for Eikon:  ID:nGNX6R5Lh3 
Further company coverage:  NOVN.O 

 ((Reuters.Briefs@thomsonreuters.com;))